AngioDynamics Long Term Debt to Equity from 2010 to 2024

ANGO Stock  USD 6.15  0.07  1.13%   
Check AngioDynamics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AngioDynamics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 17.8 M, Interest Expense of 1.7 M or Total Revenue of 242.9 M, as well as many indicators such as Price To Sales Ratio of 1.2, Dividend Yield of 0.0 or PTB Ratio of 0.93. AngioDynamics financial statements analysis is a perfect complement when working with AngioDynamics Valuation or Volatility modules.
  
Check out the analysis of AngioDynamics Correlation against competitors.
To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.

About AngioDynamics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include AngioDynamics income statement, its balance sheet, and the statement of cash flows. AngioDynamics investors use historical funamental indicators, such as AngioDynamics's Long Term Debt to Equity, to determine how well the company is positioned to perform in the future. Although AngioDynamics investors may use each financial statement separately, they are all related. The changes in AngioDynamics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on AngioDynamics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on AngioDynamics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in AngioDynamics. Please read more on our technical analysis and fundamental analysis pages.
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access and for use in oncology and surgical settings in the United States and internationally. The company was founded in 1988 and is headquartered in Latham, New York. Angiodynamics operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 760 people.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Additional Information and Resources on Investing in AngioDynamics Stock

When determining whether AngioDynamics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AngioDynamics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Angiodynamics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Angiodynamics Stock:
Check out the analysis of AngioDynamics Correlation against competitors.
To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AngioDynamics. If investors know AngioDynamics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AngioDynamics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.80)
Revenue Per Share
8.105
Quarterly Revenue Growth
(0.07)
Return On Assets
(0.05)
Return On Equity
(0.62)
The market value of AngioDynamics is measured differently than its book value, which is the value of AngioDynamics that is recorded on the company's balance sheet. Investors also form their own opinion of AngioDynamics' value that differs from its market value or its book value, called intrinsic value, which is AngioDynamics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AngioDynamics' market value can be influenced by many factors that don't directly affect AngioDynamics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AngioDynamics' value and its price as these two are different measures arrived at by different means. Investors typically determine if AngioDynamics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AngioDynamics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.